Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Tables (1-1)

Sum=33

Publishing Process of This Article

Item

Count

Browse

161

Download

Sum=197

Sep 15, 2025 (publication date) through Sep 14, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Sep 15, 2025; 16(9): 109123
Published online Sep 15, 2025. doi: 10.4239/wjd.v16.i9.109123

Table 1 Results of fat and lean (muscle) mass loss for anti-obesity agents

Drug and dosage	Treatment duration (weeks)	Mechanism of action	Indication	Body weight change from baseline (%)	Lean body mass (%) of total body mass lost
Semaglutide 24 mg[4]	68	GLP-1R agonism	Obesity (without T2DM)	-14.9	39
Tirzepatide 15 mg[5]	72	GLP-1R/GIP dual agonism	Obesity (without T2DM)	-20.9	24
Retatrutide 12 mg[14]	36	GLP-1R/GIP/glucagon triple agonism	T2DM with a BMI of 25-50 kg/m²	-16.9	33
Retatrutide 12 mg[6]	48	GLP-1R/GIP/glucagon triple agonism	Obesity (without T2DM)	-22.8	-

BMI: Body mass index; GLP-1R: Glucagon-like peptide 1 receptor; GIP: Glucose-dependent insulinotropic peptide; T2DM: Type 2 diabetes mellitus.

Citation: Cigrovski Berkovic M, Ruzic L, Cigrovski V, Strollo F. Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs. World J Diabetes 2025; 16(9): 109123
URL: https://www.wjgnet.com/1948-9358/full/v16/i9/109123.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i9.109123